Latest news with #Lo
RTHK
12 hours ago
- Politics
- RTHK
'Media should not abuse press freedom'
'Media should not abuse press freedom' Lo Wing-hung said the media won't easily violate security laws as long as they are not politically driven. Photo: RTHK Veteran journalist Lo Wing-hung said while press freedom is important, it should not be abused and and the media should always take a moderate stance. "It's like walking on a tightrope," he told RTHK's NSL Chronicles III programme. "I always think the 'middle-of-the-road' approach is the best for society's overall interests." He said press freedom comes with responsibility, describing the relationship between the two as that of "twin brothers". Lo, who's also a member of the Chinese People's Political Consultative Conference, said media outlets won't easily violate security laws so long as they're not "politically-driven". For those with a "strong political agenda", he said they'll have to make a choice going forward, either to stop doing what they are doing or run the risk of committing a crime.
Business Upturn
2 days ago
- Business
- Business Upturn
SINOVAC Announces New Board Member
Beijing, China: Sinovac Biotech Ltd. (Nasdaq: SVA) ('SINOVAC' or the 'Company'), a leading provider of biopharmaceutical products in China, today announced that it received a resignation notice from David Guowei Wang, a member of the board of directors (the 'Board') and a member of the Audit Committee, Compensation Committee and the Corporate Governance and Nominating Committee of the Board, effective immediately. Mr. Wang's resignation was due to increased professional commitments and time constraints and was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices. The Board has appointed Geoffrey C. Hsu, CFA, as a director to the Board to fill the vacancy created by such resignation under the laws of Antigua and Barbuda. Mr. Hsu has also been elected as a member of the Audit Committee, Compensation Committee and the Corporate Governance and Nominating Committee of the Board. Mr. Hsu is a General Partner and Portfolio Manager at OrbiMed, one of the world's largest dedicated healthcare investment firms, managing over $17 billion in assets. Mr. Hsu brings extensive investment experience in the biotechnology industry and China. He joined OrbiMed in 2002 and has been a Portfolio Manager since 2005, leading the public equity team's biotech and emerging markets efforts. He has been responsible for overseeing the firm's public equity investments in China since 2009 and the firm's investment in SINOVAC since 2013. Prior to joining OrbiMed, Mr. Hsu worked as a financial analyst in the healthcare investment banking group at Lehman Brothers. He received an A.B. degree summa cum laude from Harvard University and holds an M.B.A. from Harvard Business School. Following this appointment, the Board consists of four members, including Dr. Chiang Li (Chairman), Mr. Yuk Lam Lo, Mr. Sven H. Borho, CFA, and Mr. Hsu. The Audit Committee of the Board consists of three members, including Mr. Borho, Mr. Lo and Mr. Hsu. The Compensation Committee and the Corporate Governance and Nominating Committee of the Board each consists of Dr. Li, Mr. Lo and Mr. Hsu. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under 'Category 1 Preventative Biological Products' and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations. For more information, please visit the Company's website at View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Wire
2 days ago
- Business
- Business Wire
SINOVAC Announces New Board Member
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (Nasdaq: SVA) (' SINOVAC ' or the ' Company '), a leading provider of biopharmaceutical products in China, today announced that it received a resignation notice from David Guowei Wang, a member of the board of directors (the ' Board ') and a member of the Audit Committee, Compensation Committee and the Corporate Governance and Nominating Committee of the Board, effective immediately. Mr. Wang's resignation was due to increased professional commitments and time constraints and was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices. The Board has appointed Geoffrey C. Hsu, CFA, as a director to the Board to fill the vacancy created by such resignation under the laws of Antigua and Barbuda. Mr. Hsu has also been elected as a member of the Audit Committee, Compensation Committee and the Corporate Governance and Nominating Committee of the Board. Mr. Hsu is a General Partner and Portfolio Manager at OrbiMed, one of the world's largest dedicated healthcare investment firms, managing over $17 billion in assets. Mr. Hsu brings extensive investment experience in the biotechnology industry and China. He joined OrbiMed in 2002 and has been a Portfolio Manager since 2005, leading the public equity team's biotech and emerging markets efforts. He has been responsible for overseeing the firm's public equity investments in China since 2009 and the firm's investment in SINOVAC since 2013. Prior to joining OrbiMed, Mr. Hsu worked as a financial analyst in the healthcare investment banking group at Lehman Brothers. He received an A.B. degree summa cum laude from Harvard University and holds an M.B.A. from Harvard Business School. Following this appointment, the Board consists of four members, including Dr. Chiang Li (Chairman), Mr. Yuk Lam Lo, Mr. Sven H. Borho, CFA, and Mr. Hsu. The Audit Committee of the Board consists of three members, including Mr. Borho, Mr. Lo and Mr. Hsu. The Compensation Committee and the Corporate Governance and Nominating Committee of the Board each consists of Dr. Li, Mr. Lo and Mr. Hsu. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac ®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive ®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive ®, is an innovative vaccine under 'Category 1 Preventative Biological Products' and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1 ®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu ®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations. For more information, please visit the Company's website at
New Straits Times
3 days ago
- New Straits Times
School holds memorial for teacher found dead in her home
KUALA LUMPUR: A school recently held a memorial service for a teacher who was found dead alone in her home. In a Facebook post last night, the school said the ceremony held on Monday was filled with sorrow and remembrance for the late teacher, identified as Lo Kwan Fong. At 7.30am, teachers, students and guests gathered in the school hall for a moment of silent prayer. "Images of Madam Lo appeared on the screen — her familiar smile and gentle eyes — each frame a cherished memory that warmed our hearts," the post read. The service featured tributes from the principal, board chairman and representatives of the parent-teacher association. Photos and videos shared by the school showed students and staff moved to tears as they watched a video commemorating Lo's time and contributions at the school. The school said Lo's warmth, humility and dedication to education had left a lasting legacy. "Though she may no longer be with us, her kind teachings, humble example, and tireless dedication to education have left an indelible mark on the hearts of all who had the honour of walking alongside her. "Farewell, Madam Lo. You will forever remain in our hearts." In earlier reports, the police are still on the hunt for the victim's next of kin as her body remains unclaimed.
The Star
3 days ago
- Entertainment
- The Star
HK actor Henry Lo, 67, leaves TVB after 27 years: 'The elderly deserve dignity'
Hong Kong actor Henry Lo Chun-shun says a successful livestream session in mainland China can earn one up to three years' worth of TVB salary. Photo: Sin Chew Daily Hong Kong actor Henry Lo Chun-shun made headlines in April after accusing TVB of cancelling several of his show appearances, which affected his income. The matter eventually drew a response from TVB general manager Eric Tsang, who said: 'No artiste can work in this industry forever.' At the time, Lo, 67, shared that his contract was nearing its end. Now, his name has been completely removed from TVB's artiste directory. In an interview with HK01, Lo confirmed that he has officially parted ways with the broadcaster after 27 years, saying there was no need for contract renewal discussions. 'As the contract neared its end, the company simply called me in to settle my Mandatory Provident Fund (MPF). Once everything was calculated, it was over,' he said. On whether he was disappointed with the decision, the State Of Divinity (1996) star answered: 'No, I've become indifferent. It felt normal to me.' Lo revealed that he has been filming commercials in mainland China recently and is now eyeing the livestreaming scene, noting that a single successful session could earn him up to three years' worth of TVB salary. The actor also shared that several of his elderly TVB colleagues are also preparing to make similar transitions. 'Of course, my life was affected by (the low income). Otherwise, I wouldn't have spoken up the way I did. It really disrupted my basic living expenses.' Describing the entertainment industry as 'ruthless,' Lo said many artistes tend to be forgotten quickly once they leave. 'I hope someone remembers me while I'm still alive. Old people also deserve dignity. Don't let others tear you down. My life is mine to arrange,' he added.
